Phase 2 Open Label Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)

Inclusion Criteria: * Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any trial-related procedures. * Subjects must be willing to comply with all trial procedures and must be available for the duration of the trial. * Male or female subject aged 18 years of age or older at the time of consent. * Female subject of childbearing potential has had a negative serum pregnancy test at screening and negative urine pregnancy test at Day 1. * Subject has clinically confirmed diagnosis of FFA based on investigator judgment. * Subject has a target area with moderate to severe perifollicular erythema and/or scale at Screening and Day 1. * For subject who uses make-up, moisturizers, creams, lotions, cleansers, and/or sunscreens on the face, subject has used the same product brands/types for a minimum period of 4 weeks prior to Day 1, agrees not to change brand/type or frequency of use throughout the trial, agrees not to apply those products on the treated area during the trial, and agrees not to use make-up, moisturizers, creams, lotions, cleansers, and/or sunscreens on the face on the clinic visit days before the visit. * Subject is willing to maintain a consistent hair style and hair style regimen, including shampoo and hair products (including hair dye, process, and timing to hair appointments), and to refrain from weaves or extensions throughout the course of the trial and for 4 weeks prior to Day 1. Note: Hair dying…